OptiBiotix Health PLC Result of AGM (7603E)
09 Luglio 2021 - 11:49AM
UK Regulatory
TIDMOPTI
RNS Number : 7603E
OptiBiotix Health PLC
09 July 2021
Opti B i otix Health plc
( ÒOpti Bi o t ixÓ or the ÒCompanyÓ)
Result of AGM
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high
choleste r ol, diabetes and skincare, a nnounces that at the
Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions
were duly passed.
As shareholders were unable to attend the AGM in person as a
result of the ongoing pandemic, they were given the option to
submit questions in advance. These questions have been addressed
and will be available to view on the website, along with the voting
results, later today:
https://www.optibiotix-ir.com/content/investors/shareholder-information
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which
modify the human microbiome Ð the collective genome
of the microbes in the body Ð in order to prevent and
manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading
academics in the development of microbial strains, compounds,
and formulations which are used as active ingredients and
supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix
to incorporate their human microbiome modulators into a
wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The CompanyÕs current
areas of focus include obesity, cardiovascular health, and
diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGRLMLTMTIMMPB
(END) Dow Jones Newswires
July 09, 2021 05:49 ET (09:49 GMT)
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Mar 2023 a Mar 2024